(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...
AbbVie Receives Orphan Drug Designation for HUMIRA(R) (adalimumab) from the U.S. Food and Drug Administration for the Investigational Treatment of Certain Forms of Non-infectious Uveitis NORTH CHICAGO ...
Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...
GoodRx is joining forces with drugmaker Boehringer Ingelheim to make its Humira biosimilar adalimumab available at an affordable price. The pharmaceutical company will offer citrate-free ...
A Humira biosimilar, produced by drug maker Sandoz, has been given the green light from the US Food and Drug Administration (FDA). Sandoz, a division of Novartis, confirmed that the FDA granted ...
A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results